Vertigenius, the pioneering MedTech company transforming the treatment of vertigo, today announces the successful close of a €2.55M funding round to drive its growth in the US. The investment – which follows a €2.1M fundraising round in 2024 – was led by Atlantic Bridge and supported by Enterprise Ireland, MedTech Syndicate, IRRUS Investments, Xcendra Ventures, Ascentifi and others.
Vertigo is a common, highly treatable, but often debilitating condition affecting 390 million people worldwide. Causes include concussion, traumatic brain injury, and the natural degradation of the balance system with age. While most patients recover through referral to a vestibular therapist and home-based rehabilitation exercises, there has been no means of remotely monitoring patient progress, until now.
Vertigenius transforms the delivery of care for vertigo patients by enabling remote monitoring for the first time. The wearable head sensor medical device allows clinicians to track patients’ at-home treatment remotely, monitor progress and adjust prescribed treatment accordingly. By accelerating clinician workflows and reducing the number of clinic visits required, Vertigenius eases critically long waiting lists to see vestibular therapists, and supports overstretched teams. Additionally, in the US, clinics can access additional insurance reimbursement1 for remote monitoring of patients, opening up previously unavailable income streams.
With FDA registration complete, Vertigenius launched in the US market in October 2025. Already, 20 clinics across 11 US states are now using the Vertigenius medical device and 3,000 patients have been treated. The US represents a lucrative market opportunity for Vertigenius, with an addressable market of over €3BN and a network of more than 5,000 vestibular clinics. Expansion there is therefore a key focus for this latest funding round. Over the next five years, Vertigenius anticipates expanding further in Europe and entering other markets including Asia Pacific to transform the treatment of vertigo globally.
Vertigenius will use the new funding to build on this initial success and grow its US commercial team, including two US sales directors who have just joined the Vertigenius team. The investment will also fund hiring in clinical research, product R&D, quality assurance and regulatory affairs, all of which will continue to be based in the company’s Irish headquarters.
Mark Barry, CEO, Vertigenius, said: “For the first time, clinicians have a direct view of at-home patient treatment. By transforming real-time data into clinically relevant insights, providers can now proactively tailor treatments and significantly elevate the standard of patient care that they are providing.
“This investment marks an exciting new chapter for Vertigenius as we move into the world’s largest market for vestibular care. The early traction we have seen in the US validates both the clinical value of our platform and the commercial opportunity.”
Conor O’Sullivan, Investment Director, Atlantic Bridge, said: “Vertigenius is addressing a significant gap in vestibular care in a multi-billion dollar market. The team has built a unique platform that is significantly enhancing the delivery of vestibular care by supporting clinicians and patients between visits, and we are excited to back their U.S. expansion.”